Gilead's Chemical Compounds for Treating HIV Infections

This patent covers specific chemical structures designed to block HIV from replicating in human cells, providing a foundation for new antiviral medications.

What it covers

This patent claims specific chemical structures known as substituted octahydropyrido-pyrazino-oxazepines. These molecules act as inhibitors, which means they are designed to bind to viral proteins to stop the HIV virus from completing its life cycle. By preventing the virus from integrating its genetic material into the host cell, these compounds help reduce the viral load in a patient. The patent also covers the pharmaceutical formulations, such as pills or liquids, that combine these active chemical compounds with carriers or diluents for safe delivery into the body.

What it doesn't cover

• —Does not cover general classes of HIV drugs like protease inhibitors or reverse transcriptase inhibitors.
• —Does not cover the biological process of HIV infection itself.
• —Does not cover other chemical structures that fall outside the specific formula defined in the claims.
• —Does not cover methods of manufacturing the chemical precursors used to synthesize these compounds.

The clever bit

The innovation lies in the specific tricyclic scaffold—the octahydropyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine core—which provides a rigid, three-dimensional shape that fits precisely into the viral enzyme's active site, blocking its function more effectively than previous, more flexible molecules.

Why it matters

Gilead Sciences is a leader in HIV therapy, and this patent represents the intellectual property protecting specific candidates in their drug development pipeline. These compounds are part of the ongoing effort to create more effective, better-tolerated, or longer-lasting treatments for HIV patients. Such patents are essential for pharmaceutical companies to justify the massive costs of clinical trials and regulatory approval.

Real-world examples

• 1.Experimental HIV antiviral drug candidates
• 2.Pre-clinical pharmaceutical research compounds